{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T05:39:38Z","timestamp":1781415578980,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Health Commission of Jiading District, Shanghai","award":["2022-KY-03"],"award-info":[{"award-number":["2022-KY-03"]}]},{"name":"Health Commission of Jiading District, Shanghai","award":["2021-KY-11"],"award-info":[{"award-number":["2021-KY-11"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-81537-1","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T05:37:34Z","timestamp":1732858654000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of haemoglobinA1c on platelet reactivity and cardiovascular outcomes in patients undergoing drug-eluting stent implantation"],"prefix":"10.1038","volume":"14","author":[{"given":"Yilin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"81537_CR1","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2147\/IJGM.S450059","volume":"17","author":"Y Mao","year":"2024","unstructured":"Mao, Y., Zhu, B., Wen, H., Zhong, T. & Bian, M. Impact of platelet hyperreactivity and diabetes mellitus on ischemic stroke recurrence: a single-center cohort clinical study. Int. J. Gen. Med. 17, 1127\u20131138 (2024).","journal-title":"Int. J. Gen. Med."},{"issue":"5","key":"81537_CR2","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/dme.14291","volume":"37","author":"RC Sagar","year":"2020","unstructured":"Sagar, R. C., Naseem, K. M. & Ajjan, R. A. Antiplatelet therapies in diabetes. Diabet. Med. 37(5), 726\u2013734 (2020).","journal-title":"Diabet. Med."},{"issue":"3","key":"81537_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.thromres.2011.11.052","volume":"129","author":"N Vazzana","year":"2012","unstructured":"Vazzana, N., Ranalli, P., Cuccurullo, C. & Dav\u00ec, G. Diabetes mellitus and thrombosis. Thromb. Res. 129(3), 371\u2013377 (2012).","journal-title":"Thromb. Res."},{"key":"81537_CR4","doi-asserted-by":"publisher","first-page":"1447e1455","DOI":"10.1016\/j.jacc.2010.03.103","volume":"56","author":"G Campo","year":"2010","unstructured":"Campo, G. et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T\/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and\/or resistance to clopidogrel) trial substudy. J. Am. Coll. Cardiol. 56, 1447e1455 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"81537_CR5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","volume":"124","author":"MJ Price","year":"2011","unstructured":"Price, M. J. et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNowP2Y12 assay: impact on thrombosis and safety (GRAVITAS). Trial Circ. 124, 1132\u20131137 (2011).","journal-title":"Trial Circ."},{"key":"81537_CR6","doi-asserted-by":"publisher","first-page":"7261","DOI":"10.3390\/ijms23137261","volume":"23","author":"A Nusca","year":"2022","unstructured":"Nusca, A. et al. Glycemic control in patients undergoing percutaneous coronary intervention: what is the role for the novel antidiabetic agents? A comprehensive review of basic scienceand clinical data. Int. J. Mol. Sci. 23, 7261 (2022).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"81537_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12933-023-01976-4","volume":"22","author":"HS Kim","year":"2023","unstructured":"Kim, H. S. et al. Implication of diabetic status on platelet reactivity and clinical outcomes after drug-eluting stent implantation: results from the PTRG-DES consortium. Cardiovasc. Diabetol. 22(1), 245 (2023).","journal-title":"Cardiovasc. Diabetol."},{"issue":"5","key":"81537_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3349\/ymj.2022.63.5.413","volume":"63","author":"AY Her","year":"2022","unstructured":"Her, A. Y., PTRG-DES Consortium investigators et al. Platelet function and genotype after DES implantation in East Asian patients: rationale and characteristics of the PTRG-DES Consortium. Yonsei Med. J. 63(5), 413\u2013421 (2022).","journal-title":"Yonsei Med. J."},{"key":"81537_CR9","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1007\/s00125-012-2584-3","volume":"55","author":"C Andersson","year":"2012","unstructured":"Andersson, C. et al. Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia 55, 2348\u20132355 (2012).","journal-title":"Diabetologia"},{"issue":"1","key":"81537_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12933-021-01413-4","volume":"20","author":"C Sinning","year":"2021","unstructured":"Sinning, C. et al. Association of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium. Cardiovasc. Diabetol. 20(1), 223 (2021).","journal-title":"Cardiovasc. Diabetol."},{"issue":"4","key":"81537_CR11","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.3346\/jkms.2023.38.e24","volume":"38","author":"H Kim","year":"2023","unstructured":"Kim, H. et al. Long-term risk of cardiovascular disease among type 2 diabetes patients according to average and visit-to-visit variations of HbA1c levels during the first 3 years of diabetes diagnosis. J. Korean Med. Sci. 38(4), e24 (2023).","journal-title":"J. Korean Med. Sci."},{"key":"81537_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11239-010-0547-4","volume":"32","author":"F Mangiacapra","year":"2011","unstructured":"Mangiacapra, F. et al. Lack of correlation between platelet reactivity and glycemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel. J. Thromb. Thrombolysis 32, 54\u201358 (2011).","journal-title":"J. Thromb. Thrombolysis"},{"key":"81537_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12933-015-0244-x","volume":"14","author":"G Shlomai","year":"2015","unstructured":"Shlomai, G. et al. High-risk type-2 diabetes mellitus patients, without prior ischemic events, have normal blood platelet functionality profiles: a cross-sectional study. Cardiovasc. Diabetol. 14, 80 (2015).","journal-title":"Cardiovasc. Diabetol."},{"key":"81537_CR14","doi-asserted-by":"crossref","unstructured":"Joelle Singer, A. W. et al. Effect of intensive glycemic control on platelet reactivity in patients with long-standing uncontrolled diabetes. Thromb. Res. 134(1), 121\u2013124 (2014).","DOI":"10.1016\/j.thromres.2014.05.010"},{"key":"81537_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1464-5491.2011.03456.x","volume":"29","author":"L Xu","year":"2012","unstructured":"Xu, L. et al. Association between HbA1c and cardiovascular disease mortality in older Hong Kong Chinese with diabetes. Diabet. Med. 29, 393\u2013398 (2012).","journal-title":"Diabet. Med."},{"issue":"19","key":"81537_CR16","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.4103\/0366-6999.190664","volume":"129","author":"Y Yao","year":"2016","unstructured":"Yao, Y. et al. Head-to-head comparison of two point-of-care platelet function tests used for assessment of on-clopidogrel platelet reactivity in Chinese acute myocardial infarction patients undergoing percutaneous coronary intervention. Chin. Med. J. (Engl). 129(19), 2269\u20132274 (2016).","journal-title":"Chin. Med. J. (Engl)"},{"key":"81537_CR17","doi-asserted-by":"crossref","unstructured":"Madsen, E. H. et al.  Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, verifynow, and thrombelastography in patients undergoing percutaneous coronary intervention. Clin. Chem. 56(5), 839\u2013847 (2010).","DOI":"10.1373\/clinchem.2009.137471"},{"key":"81537_CR18","doi-asserted-by":"publisher","first-page":"1901256","DOI":"10.1155\/2022\/1901256","volume":"2022","author":"R Chang","year":"2022","unstructured":"Chang, R. et al. Relationship between CYP2C19 polymorphism and clopidogrel resistance in patients with coronary heart disease and ischemic stroke in China. Genet. Res. (Camb). 2022, 1901256 (2022).","journal-title":"Genet. Res. (Camb)"},{"issue":"1","key":"81537_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12920-024-01936-1","volume":"17","author":"J Kim","year":"2024","unstructured":"Kim, J. et al. Molecular genomic and epigenomic characteristics related to aspirin and clopidogrel resistance. BMC Med. Genom. 17(1), 166 (2024).","journal-title":"BMC Med. Genom."},{"issue":"7","key":"81537_CR20","first-page":"1580","volume":"13","author":"HUH Virk","year":"2023","unstructured":"Virk, H. U. H. et al. Dual antiplatelet therapy: a concise review for clinicians. Life (Basel) 13(7), 1580 (2023).","journal-title":"Life (Basel)"},{"issue":"1","key":"81537_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12933-019-0952-8","volume":"18","author":"A Nusca","year":"2019","unstructured":"Nusca, A. et al. Incremental role of glycemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention. Cardiovasc. Diabetol. 18(1), 147 (2019).","journal-title":"Cardiovasc. Diabetol."},{"key":"81537_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"SR Mehta","year":"2001","unstructured":"Mehta, S. R. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358, 527\u2014533 (2001).","journal-title":"Lancet"},{"issue":"9","key":"81537_CR23","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1097\/CM9.0000000000000210","volume":"132","author":"Q Ma","year":"2019","unstructured":"Ma, Q. et al. Clinical outcomes and predictive model of platelet reactivity to clopidogrel after acute ischemic vascular events. Chin. Med. J. (Engl) 132(9), 1053\u20131062 (2019).","journal-title":"Chin. Med. J. (Engl)"},{"issue":"9","key":"81537_CR24","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.3390\/genes11091068","volume":"11","author":"TO Bergmeijer","year":"2020","unstructured":"Bergmeijer, T. O. et al. Effect of CYP3A4*22 and PPAR-\u03b1 genetic variants on platelet reactivity in patients treated with clopidogrel and lipid-lowering drugs undergoing elective percutaneous coronary intervention. Genes (Basel) 11(9), 1068 (2020).","journal-title":"Genes (Basel)"},{"issue":"1","key":"81537_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12872-018-0820-6","volume":"18","author":"PK Bundhun","year":"2018","unstructured":"Bundhun, P. K. & Huang, F. Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis. BMC Cardiovasc. Disord. 18(1), 78 (2018).","journal-title":"BMC Cardiovasc. Disord."},{"key":"81537_CR26","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","volume":"31","author":"S James","year":"2010","unstructured":"James, S. et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient outcomes (PLATO) trial. Eur. Heart J. 31, 3006\u20133016 (2010).","journal-title":"Eur. Heart J."},{"issue":"11","key":"81537_CR27","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1111\/jdi.13882","volume":"13","author":"Y Hiromine","year":"2022","unstructured":"Hiromine, Y. et al. Poor glycemic control rather than types of diabetes is a risk factor for Sarcopenia in diabetes mellitus: the MUSCLES-DM study. J. Diabetes Investig. 13(11), 1881\u20131888 (2022).","journal-title":"J. Diabetes Investig."},{"issue":"4","key":"81537_CR28","doi-asserted-by":"publisher","first-page":"e011295","DOI":"10.1161\/JAHA.118.011295","volume":"8","author":"S Raghavan","year":"2019","unstructured":"Raghavan, S. et al. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. J. Am. Heart Assoc. 8(4), e011295 (2019).","journal-title":"J. Am. Heart Assoc."},{"issue":"9","key":"81537_CR29","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41574-022-00690-7","volume":"18","author":"D Tomic","year":"2022","unstructured":"Tomic, D., Shaw, J. E. & Magliano, D. J. The burden and risks of emerging complications of diabetes mellitus. Nat. Rev. Endocrinol. 18(9), 525\u2013539 (2022).","journal-title":"Nat. Rev. Endocrinol."},{"key":"81537_CR30","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.3390\/jcm12134530","volume":"12","author":"BK Chyrchel","year":"2023","unstructured":"Chyrchel, B. K. et al. Association of ADP-induced whole-blood platelet aggregation with serum low-density lipoprotein cholesterol in patients with coronary artery disease when receiving maintenance ticagrelor-based dual antiplatelet therapy. J. Clin. Med. 12, 4530 (2023).","journal-title":"J. Clin. Med."},{"issue":"2","key":"81537_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/cpt.2797","volume":"113","author":"A Kumar","year":"2023","unstructured":"Kumar, A. et al. Comparative effectiveness of ticagrelor, prasugrel, and clopidogrel for secondary prophylaxis in acute coronary syndrome: a propensity score-matched cohort study. Clin. Pharmacol. Ther. 113(2), 401\u2013411 (2023).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"81537_CR32","doi-asserted-by":"publisher","first-page":"e014411","DOI":"10.1161\/JAHA.119.014411","volume":"9","author":"NW van der Hoeven","year":"2020","unstructured":"van der Hoeven, N. W. et al. Platelet inhibition, endothelial function, and clinical outcome in patients presenting with ST-segment-elevation myocardial infarction randomized to ticagrelor versus prasugrel maintenance therapy: long-term follow-up of the rEDUCE-MVI trial. J. Am. Heart Assoc. 9(5), e014411 (2020).","journal-title":"J. Am. Heart Assoc."},{"issue":"10","key":"81537_CR33","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/jamacardio.2021.2228","volume":"6","author":"JJ Coughlan","year":"2021","unstructured":"Coughlan, J. J. et al. Ticagrelor or prasugrel for patients with acute coronary syndrome treated with percutaneous coronary intervention: a prespecified subgroup analysis of a randomized clinical trial. JAMA Cardiol. 6(10), 1121\u20131129 (2021).","journal-title":"JAMA Cardiol."},{"key":"81537_CR34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1160\/TH10-07-0440","volume":"105","author":"J Jaitner","year":"2011","unstructured":"Jaitner, J. et al. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thromb. Hemost. 105, 107\u2013112 (2011).","journal-title":"Thromb. Hemost."},{"issue":"5","key":"81537_CR35","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/cpt.1911","volume":"108","author":"SS Verma","year":"2020","unstructured":"Verma, S. S. et al. Genomewide association study of platelet reactivity and cardiovascular response in patients treated with clopidogrel: a study by the International Clopidogrel Pharmacogenomics Consortium. Clin. Pharmacol. Ther. 108(5), 1067\u20131077 (2020).","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81537-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81537-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81537-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T06:04:14Z","timestamp":1732860254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81537-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["81537"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-81537-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4773150\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"20 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocols were approval by the Ethics Committee of Jiading Branch of Shanghai General Hospital and performed in accordance with the Declaration of Helsinki. All participants provided written informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"29699"}}